HD Insights

About HD Insights

HD Insights is a global research periodical aimed at HD researchers and clinicians around the world. It is distributed to more than 2,800 people across six continents.


Current Issue: HD Insights | Volume 17

HD Insights Volume 17 (PDF)

May 30th, 2017 Heather Hare For a non-PDF version of HD Insights Vol. 17, click here.

FDA approves deutetrabenazine (AUSTEDO™) to treat chorea

May 30th, 2017 Heather Hare On April 3, 2017, the FDA approved a new drug, deutetrabenazine, to treat HD-associated chorea. By: Sara LaJeunesse, MSc Deutetrabenazine (AUSTEDO™, see HD Insights, Vol. 7) is the first deuterated product approved by the FDA, and only the second product specifically approved for symptomatic treatment of HD. The pivotal clinical trial, designed and conducted by
+ Read More

Meet the Scientist : Beverly Davidson

May 30th, 2017 Heather Hare VITAL SIGNS NAME: Beverly Davidson, PhD TITLE: Chief Scientific Strategy Officer at the Children’s Hospital of Philadelphia (CHOP); Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics; Arthur V. Meigs Chair in Pediatrics, CHOP; Professor of Pathology and Laboratory Medicine, University of Pennsylvania EDUCATION: PhD and post-doctoral research fellowship, University of Michigan
+ Read More

Game-changing gene-silencing therapies for HD

May 30th, 2017 Heather Hare VITAL SIGNS NAME: Amber Southwell, PhD TITLE: Assistant Professor of Neuroscience, Burnett School of Biomedical Sciences, University of Central Florida EDUCATION: PhD, California Institute of Technology; post-doctoral research fellowship, University of British Columbia HOBBIES: Scuba diving, sailing, partnered dancing, and cooking The landscape of therapeutic development for genetic disease is rapidly evolving, and scientists are
+ Read More

Research Round-Up

May 30th, 2017 Heather Hare By: Lise Munsie, PhD In neurons… The HD Induced Pluripotent Stem Cell (iPSC) consortium differentiated HD patient iPSCs into neuronal cultures.1 RNA-seq and ChIP-seq analysis from these cultures indicated subtle alterations in expression and epigenetic signature of genes involved in neural development, function, and striatal maturation in the presence of mHTT. The small molecule isoxazole-9
+ Read More

Highlights of CHDI

May 30th, 2017 Heather Hare The 12th Annual CHDI HD Therapeutics Conference was held in St. Julian’s, Malta, April 24–27, 2017. By: Nicholas Caron, PhD The 12th Annual CHDI HD Therapeutics Conference in the town of St. Julian’s, Malta, welcomed scientists from academia and industry to present data and discuss current research aimed at treating HD. The conference opened with
+ Read More

HD Research Around the World: Brazil

May 30th, 2017 Heather Hare By: Irina Kerkis, PhD Little is known formally about the exact number of HD patients and individuals at risk in Brazil, but efforts are underway to change this. In 1997, Dr. Monica Santoro Haddad helped to start the Associação Brasil Huntington (ABH), or the Brazil Huntington Association, in São Paulo, Brazil, where she serves as
+ Read More

Highlights from the Journal of HD

May 30th, 2017 Heather Hare By: Jennifer A. Simpson, LMSW and George J. Yohrling, PhD Original Article: Simpson JA, Lovecky D, Kogan J, et al. Survey of the Huntington’s Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. J Huntingtons Dis. 2016 Dec 15;5(4):395-403. In 2012, the US Food and Drug Administration (FDA) launched a Patient-Focused Drug
+ Read More

Editor’s Letter

May 30th, 2017 Heather Hare Welcome to the 17th edition of HD Insights, timed for release at the 21st International Congress of Parkinson Disease and Movement Disorders in Vancouver, BC. We continue our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers.  In this edition, we continue
+ Read More

Thank you to Teva Pharmaceuticals

February 22nd, 2017 Heather Hare HD Insights thanks Teva for its ongoing support Teva CNS is committed to continued research and development of its product portfolio and to the development of medicines aimed at meeting the specific needs of the patient communities it serves. Teva’s legacy in CNS is grounded in its commitment to ongoing collaboration with academia, medical institutions and patient
+ Read More